Alissa Neufeld, who identifies her role as General Counsel of Lifevantage Corp (LFVN), reported a sale of 1,283 shares of the company's common stock on 10/01/2025 at a reported price of $9.56 per share. After the transaction the filing shows Ms. Neufeld beneficially owns 116,977 shares. The Form 4 is signed and dated 10/03/2025, indicating timely disclosure under Section 16 reporting requirements.
On 10/01/2025 Steven R. Fife, who is listed as President and CEO and a Director of Lifevantage Corp (LFVN), reported a sale of 8,181 shares of the company's common stock at a price of $9.56 per share. After the reported transaction, Mr. Fife's beneficial ownership is listed as 752,820 shares. The Form 4 was signed by a power of attorney on 10/03/2025.
Lifevantage Corp insider Carl Aure, the company's Chief Financial Officer, reported a sale of 1,361 shares of Common Stock on 10/01/2025 at a price of $9.56 per share. The Form 4 shows 159,969 shares remained beneficially owned by Mr. Aure after the transaction. The filing was signed by Alissa Neufeld as Power of Attorney on 10/03/2025.
Julie Boyster, listed as the Chief Marketing Officer of Lifevantage Corp (LFVN), reported a sale of company common stock on 10/01/2025. The Form 4 shows she disposed of 1,835 shares at a price of $9.56 per share. After the transaction she beneficially owned 150,088 shares, held directly. The filing was signed by a power of attorney on 10/03/2025. The form is a standard Section 16 filing reporting insider changes in beneficial ownership and contains no additional remarks or derivative transactions.
The Capital Management Corporation reported beneficial ownership of 2,064,176 shares of LifeVantage Corporation common stock, representing 16.3% of the class. The filing shows the filer has sole voting power over 2,041,176 shares and sole dispositive power over 2,064,176 shares. The statement is filed on a Schedule 13G/A for the reporting period ending September 30, 2025 and includes a signed certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Contact and registration details identify Pamela C. Simms as Compliance Officer for The Capital Management Corporation, organized in Virginia.
LifeVantage Corporation is asking shareholders to vote on four routine proposals at its annual meeting, including election of seven directors and approval of an amendment to its 2017 Long-Term Incentive Plan that would add 400,000 shares to the reserve and extend the plan term to December 5, 2031. As of the Record Date, 12,691,009 shares were outstanding. The Board reports 71,500 option shares and 811,576 restricted stock/RSU awards outstanding under the plan and states 1,152,619 shares are available assuming maximum performance or 1,460,207 shares assuming target performance. The company reports a fair market stock price of $10.68 on the Record Date and estimates potential dilution would rise from 18.5% to 21.6% if the amendment is approved. The proxy describes executive pay structure changes (more PRSUs versus RSUs), recent dividend increases totaling $2.1M, and share repurchases of $3.1M (about 0.3M shares).
Darwin Lewis, a director of Lifevantage Corp (LFVN), reported an automatic purchase of common stock under a Rule 10b5-1 trading plan. On 09/16/2025 he acquired 450 shares at a price of $10.8499 per share, bringing his total beneficial ownership to 117,217 shares. The filing states the 10b5-1 plan was adopted on February 10, 2025. The Form 4 was signed on behalf of Mr. Lewis by a power of attorney on 09/18/2025. The report lists the transaction as a non-derivative acquisition and identifies Mr. Lewis as a director of the issuer.
Lifevantage Corp (LFVN) director Michael A. Beindorff reported insider sales on 09/09/2025. The Form 4 shows two open-market dispositions: 4,125 shares sold at $11.44 and 200 shares sold at $11.35. After these transactions, the filing reports 22,858 shares held directly by Mr. Beindorff and indirect holdings that include 126 shares held by spouse as custodian for minor children, 91,413 shares held by a trust, and 5,500 shares held indirectly by spouse. The filing notes the trust is the Michael A. Beindorff Trust dated 06/14/2000, of which the reporting person and his spouse are trustees.
LifeVantage Corporation disclosed that on September 4, 2025 it issued a press release announcing its financial results for the fourth quarter and full fiscal year ended June 30, 2025. The press release is included as Exhibit 99.1 to the current report. The filing notes the furnished information is not being deemed "filed" under the Exchange Act and therefore is not subject to the liabilities of Section 18.
LifeVantage Corporation describes its direct-selling dietary supplement and personal-care business, emphasizing a nutrigenomics "activating wellness" strategy and product portfolio including Protandim4, TrueScience4 skin and hair care, AXIO4 energy drinks, Petandim4, and the patent-pending MindBody GLP-1 System42; MB Core42; MB Enhance42. The company reported approximately $220.0 million aggregate market value of common stock held by non-affiliates as of December 31, 2024 and 12,691,009 shares outstanding as of September 3, 2025. As of June 30, 2025 it employed 238 people and had ~51,000 active independent consultants (vs 49,000 in fiscal 2024). Approximately 22% of fiscal 2025 revenue was international, primarily Japan. There was no outstanding balance on the 2024 Credit Facility as of June 30, 2025; the facility matures April 12, 2027. The filing lists material risks including dependence on independent consultants, concentration on a few products, third-party manufacturing and supply-chain risks, regulatory and advertising scrutiny, cybersecurity and data-privacy obligations, potential tax or employment classification exposure for consultants, activist stockholder actions, and foreign currency and market-entry risks.